Do we like Shinya Yamanaka?
Our score: 7 out of 10. A Nobel-winning scientist with no harmful words or company found, held back by thin public record on values and an unresolved integrity dispute.
Yamanaka did not plan to be a lab scientist. He trained as an orthopaedic surgeon and has said he did not expect to do science, and the early years of his research career were rough.
The messy bit is recent. On 7 August 2026 Gotham City Research, a U.S. short-seller, released a report alleging image duplication in ten papers dated between 2000 and 2020. Its founder told Retraction Watch the firm has shorted Sumitomo Chemical and Sumitomo Pharma, which fund CiRA. So treat the source with some salt, though that doesn't settle whether the papers need a look.
CiRA's reply, dated 9 August, says Yamanaka is first or corresponding author on only three of the ten papers. On five he is a co-author for supplying materials, and on two he is not an author at all. Two were already reviewed, and he concluded one pair of images is not identical. CiRA objects to lumping the cases together as a pattern, saying questioning someone's integrity without sufficient basis is unacceptable.
The cloud isn't new. A colleague at his institute was disciplined after a paper he did not coauthor was retracted over a misconduct finding, and the statement says Yamanaka received no formal sanction. Several papers have been corrected, and others are being reviewed by their own authors. Nothing has been found against Yamanaka himself, and the matter is unresolved.
On the harm test, there's honestly not much to report. Searches for anything he has said or done about LGBTQ+ people, women, migrants, vaccines or climate turned up nothing harmful, and no troubling company in his work. That's a thin record rather than a glowing one, so a pass, not a distinction.
The good stuff is the work itself. In March 2026 Japan gave conditional approval to the first iPS-cell-based therapies, including one for Parkinson's disease, which grew out of the technology he pioneered. That is a Nobel idea reaching patients, with the safety caveats that come with a conditional approval.